“This bill is more than a policy change—it offers real hope to so many people who desperately need it.”
By Jack Gorsline, Filter
The Oklahoma State Senate voted on April 29 to pass the Oklahoma Breakthrough Therapy Act. Formally known as House Bill 3834, the measure authorizes the use of state funds to support trials focused on ibogaine—the powerful, naturally occurring psychedelic compound.
The bill passed the House in March. If signed into law by Governor Kevin Stitt (R), it will mark a significant shift in Oklahoma’s approach to the ongoing crises around mental health and substance use disorders.
It would authorize the State Department of Health to enter into contracts with drug developers to conduct extensive, state-monitored clinical trials for ibogaine-based therapeutics. Lawmakers who championed the bill argue that traditional treatment methods have consistently fallen short, necessitating a research-driven exploration of breakthrough therapies.
The legislation is also designed to facilitate collaboration with other states currently conducting similar clinical research, creating a multistate consortium aimed at securing federal regulatory approval.
Ibogaine is derived from the root bark of the iboga shrub. For decades, the compound has shown observational promise in interrupting severe substance use disorders—particularly opioids—and alleviating post-traumatic stress disorder and
Read full article on Marijuana Moment
